Chemoradiation for Limited Stage Small Cell Lung Cancer: Are You CONVERTed?

For our September #radonc journal club we will discuss twice-daily versus daily chemoradiation for limited stage small cell lung cancer (LS-SCLC). Twice-daily radiation has been controversial for some time – do the results of the CONVERT trial mean the debate is settled?

Our article is:

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

The article is free for download, thanks to the CONVERT Study Team and The Lancet Oncology. For the protocol and supplementary materials, click here.

The lead author, Prof Corinne Faivre-Finn PhD of the Christie NHS Foundation Trust, will join us for the weekend and will discuss at a live journal hour Sunday September 17th at 11AM- 12PM Central Standard Time, 5-6 PM London. We will focus on the following topics:

T1.  Chemoradiotherapy is the standard for limited stage small cell lung cancer. What do most people do currently for the radiation and chemotherapy regimens?

T2.   What were the aim and methods of this study?

T3.  What were the results, and how do they fit into current standards for treatment delivery?

T4.  Failure rates remain high in both arms. What areas of future research in radiotherapy should we pursue to further improve outcomes in LS-SCLC?

We will start open chat 6 AM CST Saturday September 16th to include global participation.

• Here are guidelines on how to sign up and participate
• Read our disclaimer for ways to keep it rewarding and professional. If you’re not ready, just lurk and tune into the conversation.
• If you feel like getting fancy, feel free to add #lcsm to your tweets and share with the lung cancer community on twitter. Just don’t forget the #radonc tag!

Any suggestions? Leave a comment or tweet us at @Rad_Nation. And please join us this weekend!